Celltrion licenses in microbiome drug candidates from KoBioLabs

Celltrion said Wednesday it has signed a license-in agreement with Korean biopharma company KoBioLabs for three microbiome-based drug candidates targeting intestinal diseases. The signing ceremony was held at Celltrion’s Global Biotechnology Research Center, attended by Executive Vice President Seo Jin-seok and KoBioLabs CEO Ko Kwang-pyo. Under the deal, valued at up to 205.2 billion won ($136.8 million), Celltrion secured exclusive rights to develop and commercialize KoBioLabs candidates KC84,

By The Korea Herald